Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GX-BP1 + carboplatin + paclitaxel
- Development stage
- Preclinical
- Lead developer
- Genexine
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
GX-BP1 + carboplatin + paclitaxel is an investigational combination regimen consisting of Genexine's first-in-class bioPROTAC candidate GX-BP1 and the standard chemotherapies carboplatin and paclitaxel. GX-BP1 is an mRNA-encoded fusion protein delivered via a lung-targeted lipid nanoparticle (LNP) system. It is designed to selectively degrade SOX2, a transcription factor associated with tumor progression, cancer stemness, and therapeutic resistance, via the ubiquitin-proteasome system. Carboplatin is a platinum-based DNA alkylating agent, and paclitaxel is a microtubule-stabilizing taxane. In preclinical models, the combination of GX-BP1 with carboplatin and paclitaxel demonstrated synergistic anti-tumor activity, achieving 87% to 96% tumor growth inhibition (TGI) and restoring sensitivity in chemotherapy-resistant models. The regimen is being developed for the treatment of solid tumors, particularly lung cancer (such as lung squamous cell carcinoma) with SOX2-driven resistance.
- Other names
- carboplatin + paclitaxel + GX-BP1carboplatin + paclitaxel + GX-BP1 regimenGX-BP1 + carboplatin + paclitaxel regimenGX-BP1/carboplatin/paclitaxel
02
Targets
DNASOX2 (SRY-box transcription factor 2)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on GX-BP1 + carboplatin + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GX-BP1 + carboplatin + paclitaxel.